Spotlight: Joint Clinical Assessment in Europe

Joint Clinical Assessment
Welcome to The Evidence Base Spotlight on ‘Joint Clinical Assessment in Europe’.

The Joint Clinical Assessment (JCA) in Europe is set to harmonize the clinical evaluation of medicines and certain medical devices across EU member states, with the aim of reducing duplication of work and accelerating patient access. Read selected coverage from The Evidence Base, covering this important and complex topic.

For more JCA content, click here.

Thank you to our spotlight partner, Cencora.

Featured content

EU HTAMultistakeholder perspectives on preparing for EU HTA – ensuring stakeholder alignment to accelerate broad patient access

With the EU HTA Regulation coming into force in Jan 2025, there is much speculation around its implications for  market access. Here, we summarize discussions from the Cencora-sponsored session, ‘EU HTA: how to ensure stakeholder alignment on a national level to accelerate broad patient access’ at the World EPA Congress 2024.

 

Images of Herbert Altmann (from Cencora) and Matisas Olsen (from EUCOPE) with the title 'Implementation of EU Joint Clinical Assessment – ensuring readiness amongst industry and other local stakeholders: Deep dive into the Cencora exhibit hall theater session from ISPOR Europe 2023', the subject of the article.Implementation of EU Joint Clinical Assessment – ensuring readiness amongst industry and other local stakeholders: Deep dive into the Cencora exhibit hall theater session from ISPOR Europe 2023

At ISPOR Europe 2023, Cencora sponsored a session entitled ‘How to Prepare for JCA in Local Health Systems? Ensuring HTA, Payer, and Industry Readiness to Accelerate Patient Access to Innovation.’ In this deep dive, we summarize some of the discussions from Herbert Altmann and Matias Olsen.

 

Images of Tommy Bramley, Herbert Altmann and Casper Paardekooper discussing joint clinical assessmentMultistakeholder perspectives on Joint Clinical Assessment in Europe: what are the opportunities and challenges for improving patient access to new treatments?

We speak with Tommy Bramley, Herbert Altmann and Casper Paardekooper talk about opportunities and challenges for JCA.

 

European Commission publishes draft implementing act on joint clinical assessments of medicinal products

The JCA process in Europe has been subject to much speculation over the past months. Now, the European Commission has made steps towards clarifying what is expected from the JCA process by publishing the draft implementing act, providing the procedural rules and methodological details for the coordinated assessment of medicinal products.

 

Harmonizing health technology assessment in Europe: building on the legacy of EUnetHTA 21

As the EMA releases a new report highlighting achievements with the EUnetHTA 21 consortium over the past few years, we discuss the next steps towards implementing the new regulation to support harmonizing health technology assessment in Europe.

 

ISPOR Europe 2023 – inside the third plenary: The calm before the storm of EU HTA

The EU HTA Regulation was adopted in January 2022, and will be the new way of working for all member states from January 2025. The third plenary at ISPOR Europe 2023 was entitled, “The Calm Before the Storm? Delivering the New Reality for EU HTA”, and ISPOR’s new Chief Scientific Officer Laura Pizzi welcomed conference Co-Chair and moderator of the final plenary Adrian Griffin (Johnson & Johnson, UK) to the stage. introduction in January 2025.

Get in touch to discuss the opportunities available to share your expertise, contribute to this theme or to become a theme sponsor.